Sugawara S
Nihon Sanka Fujinka Gakkai Zasshi. 1981 Oct;33(10):1749-56.
Plasma RNase activity was studied in normal and females with gynecological malignancies. Basic experimental data of RNase showed linear regression to the incubation period up to 20 min., optimal pH at 8.0, maximal absorption at 260 nm and sufficient substrate concentration with 120 microgram/0.02 ml. Coefficient of variation was 6.2% (n = 15) intra-assay study. Mean plasma RNase of 32 normal subjects was 0.24 +/- 0.04 (mean +/- SD) delta OD/0.01 ml/20 min. Values deviating mean + 2SD (0.32) were regarded as abnormal. Mean value at pre-treatment was 0.27 +/- 0.04 for benign tumor and abnormal value rate was 11% (2/19). The values in cervical cancer patients were 0.29 +/- 0.06 [91.7% (11/12)] for recurrent cases. The values and abnormal rates raised as clinical stage advanced. The values were also high in advanced ovarian and endometrial cancer patients. It came into normal range with the complete surgery in early stage. Pre- and post-treatment RNase value were analysed on 29 advanced cervical, endometrial and ovarian cancer patients. Abnormal value rate was lowered from 60% (9/15) to 26.6% (4/15) in therapy-responding group, but were kept high in 14 therapy-resistant group. The value was raised again as the disease recurred. Evaluation of plasma RNase value is useful means in biochemical diagnosis and in prognosing gynecological malignancies.
研究了正常女性和患有妇科恶性肿瘤女性的血浆核糖核酸酶（RNase）活性。RNase的基础实验数据显示，在长达20分钟的孵育期内呈线性回归，最适pH为8.0，在260nm处有最大吸收，底物浓度为120微克/0.02毫升时效果最佳。批内研究的变异系数为6.2%（n = 15）。32名正常受试者的血浆RNase平均值为0.24 +/- 0.04（平均值 +/- 标准差）吸光度变化/0.01毫升/20分钟。偏离平均值 + 2标准差（0.32）的值被视为异常。良性肿瘤患者治疗前的平均值为0.27 +/- 0.04，异常值率为11%（2/19）。复发性宫颈癌患者的值为0.29 +/- 0.06 [91.7%（11/12）]。随着临床分期的进展，这些值和异常率升高。晚期卵巢癌和子宫内膜癌患者的值也很高。早期完整手术后其值恢复到正常范围。对29例晚期宫颈癌、子宫内膜癌和卵巢癌患者进行了治疗前后RNase值分析。治疗反应组的异常值率从60%（9/15）降至26.6%（4/15），但在14例治疗抵抗组中仍保持较高水平。疾病复发时该值再次升高。评估血浆RNase值是妇科恶性肿瘤生化诊断和预后判断的有用手段。
